NovoCure registered for an initial public offering that could fetch as much as $300 million for its tumor-zapping Optune brain cancer treatment as it awaits a decision from the FDA on a new indication for the device.
The federal safety watchdog granted pre-market approval for Optune in April 2011 for adult patients with glioblastoma whose cancer recurred after chemotherapy. Last April, the company applied for another indication, newly diagnosed glioblastoma, under priority review from the FDA.
Help employers find you! Check out all the jobs and post your resume.
